Press coverage about Progenics Pharmaceuticals (NASDAQ:PGNX) has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Progenics Pharmaceuticals earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.0040069839651 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- Biotech Stocks on Investors’ Radar — PDL BioPharma, Progenics Pharma, Agenus, and Aptose Biosciences – Markets Insider (markets.businessinsider.com)
- Progenics: Draining The Azedra Quagmire – Seeking Alpha (seekingalpha.com)
- Looking at the Big Picture for Progenics Pharmaceuticals, Inc. (PGNX) – StockNewsGazette (stocknewsgazette.com)
- Progenics Pharmaceuticals Inc. (PGNX) Receives Average Rating of “Buy” from Analysts (americanbankingnews.com)
- Progenics Pharmaceuticals Inc (PGNX)’s Technicals Placed in the Limelight – Sparta Review (spartareview.com)
PGNX has been the subject of a number of research reports. Aegis reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Progenics Pharmaceuticals in a report on Tuesday, August 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $15.00 price objective on shares of Progenics Pharmaceuticals in a report on Tuesday, September 5th. Needham & Company LLC reaffirmed a “strong-buy” rating and issued a $14.00 price objective on shares of Progenics Pharmaceuticals in a report on Friday, September 1st. Zacks Investment Research raised shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 5th. Finally, ValuEngine downgraded shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $12.83.
Progenics Pharmaceuticals (NASDAQ PGNX) traded down 2.95% during trading on Tuesday, reaching $6.25. 690,389 shares of the company’s stock were exchanged. Progenics Pharmaceuticals has a 52-week low of $4.60 and a 52-week high of $11.72. The stock’s 50-day moving average price is $5.96 and its 200-day moving average price is $7.65. The company’s market capitalization is $439.18 million.
Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Progenics Pharmaceuticals had a negative net margin of 6.13% and a negative return on equity of 4.11%. The company had revenue of $2.77 million during the quarter, compared to the consensus estimate of $3.34 million. During the same quarter last year, the company earned ($0.08) earnings per share. The business’s revenue was down 67.3% on a year-over-year basis. Equities analysts expect that Progenics Pharmaceuticals will post ($0.90) earnings per share for the current year.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.